Ho Leung L. Fung PhD

Ho Leung Fung

Ho Leung L. Fung
PhD


Professional Summary:

Research focuses in the PK/PD of nitric oxide donors and nitric oxide synthase inhibitors, with particular concern regarding mechanisms of tolerance. Dr. Fung is specifically characterizing genetic causes of the development of tolerance to organic nitrates and seeks methods of maximizing the formulation stability and delivery of organic nitrates for treatment of various cardiovascular disorders.

Education and Training:

  • PhD, University of Kansas (1970)
  • Certificate of Pharmacy, Victorian College of Pharmacy (1966)

Awards and Honors:

  • Distinguished Professor (2012)
  • Distinguished Service Award (2010)
  • John G. Wagner Pfizer Lectureship in Pharmaceutical Sciences (2010)
  • Honorary Doctor of Laws (2008)
  • Takeru and Aya Higuchi Memorial Award (1995)
  • Frank A. Duckworth Eminent Visiting Scholar Lecture (1994)
  • Research Achievement Award in Pharmacodynamics (1992)
  • United University Professions/State University of New York Excellence Award (1991)
  • David Guttman Lectureship (1990)
  • Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug M (1988)
  • Lakey Award (1988)
  • MERIT grant award (1988)

Research Expertise:

  • : Inhalant nitrites alter the regulation of angiogenesis genes, and this effect is governed by several factors, e.g., presence of endothelial nitric oxide synthase (eNOS), route of administration, and the tissues' oxidative state
  • : Repeated nitrite inhalations cause significant changes in the expression and activities of major hepatic detoxifying enzymes such as cytochrome P450s, glutathione-S-transferases
  • : Long-standing interests in the PK/PD of nitric oxide donors and nitric oxide synthase inhibitors, with particular concern regarding mechanisms of tolerance.
  • : Toxicokinetics and vasodilatory effects of inhalant nitrites are affected by repeated exposure

Patents:

  • METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE Docket Number: 5090 Type: Other Other Type: Continuation-in-Part (1998)
  • METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE Docket Number: 5090 Type: Other Other Type: South Africa (1996)
  • METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE Docket Number: 5090 Type: Other Other Type: PCT (1996)
  • METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE Docket Number: 5090 Type: Other Other Type: Continuation-in-Part (1995)
  • SUSTAINED RELEASE ORGANIC NITRITE THERAPY Docket Number: 5090 Type: Other Other Type: Russia (1994)
  • METHOD AND COPOSITIONS FOR TREATING IMPOTENCE Docket Number: 5090 Type: Other Other Type: India (1993)
  • METHOD OF VASODILATOR THERAPY Docket Number: 5090 Type: Other Other Type: Israel (1993)
  • METHOD OF VASODILATOR THERAPY Docket Number: 5090 Type: Other Other Type: China (1993)
  • METHOD OF VASODILATOR THERAPY Docket Number: 5090 Type: Other Other Type: Chile (1993)
  • METHOD OF VASODILATOR THERAPY Docket Number: 5090 Type: Other Other Type: Taiwan (1993)
  • SUSTAINED RELEASE ORGANIC NITRITE THERAPY Docket Number: 5090 Type: Other Other Type: Continuation-in-Part (1993)
  • METHOD OF VASODILATOR THERAPY Docket Number: 5090 Type: Other Other Type: Argentina (1993)
  • METHOD OF VASODILATOR THERAPY Docket Number: 5090 Type: Other Other Type: Mexico (1993)
  • SUSTAINED RELEASE ORGANIC NITRITE THERAPY Docket Number: 5090 Type: Other Other Type: Australia (1993)
  • SUSTAINED RELEASE ORGANIC NITRITE THERAPY Docket Number: 5090 Type: Other Other Type: PCT (1993)
  • METHOD AND COMPOSITIONS FOR TREATING IMPOTENCE Docket Number: 5090 Type: Regular (1992)
  • METHOD OF VASODILATOR THERAPY Docket Number: 5090 Type: Other Other Type: Hungary
  • SUSTAINED RELEASE ORGANIC NITRITE THERAPY Docket Number: 5090 Type: Other Other Type: New Zealand
  • SUSTAINED RELEASE ORGANIC NITRITE THERAPY Docket Number: 5090 Type: Other Other Type: Canada

Journal Articles:

  • Page NA; Fung H. Organic Nitrate Metabolism and Action: Toward a Unifying Hypothesis and the Future --A Dedication to Professor Leslie Z. Benet. 2013.
  • Mohan S; Fung H. Mechanism of Cellular Oxidation Stress Induced by Asymmetric Dimethylarginine. International Journal of Molecular Science. 2012; 13.
  • Tsou P; Page N; Lee S; Fung S; Keung W; Fung H. Differential Metabolism of Organic Nitrates by Aldehyde Dehydrogenase 1a1 and 2: Substrate Selectivity, Enzyme Inactivation, and Active Cysteine Sites. The AAPS Journal. 2011; 13.
  • Shin S; Fung H. Evaluation of an LC-MS/MS Assay for 15N-Nitrite for Cellular Studies of L-Arginine Action. Journal of Pharmaceutical and Biomedical Analysis. 2011; 56.
  • Shin S; Mohan S; Fung H. Intracellular L-arginine concentration does not determine NO production in endothelial cells: Implications on the "Arginine Paradox". Biochem Biophys Res Commun. 2011; 414.
  • Krishnatry AS; Fung S; Brazeau DA; David S; Fung H. Nitroglycerin alters matrix remodeling proteins in THP-1 human macrophages and plasma metalloproteinase activity in rats. Nitric Oxide. 2011; 24.
  • Krishnatry AS; Brazeau DA; Fung H. Broad Regulation of Matrix and Adhesion Molecules in THP-1 Human Macrophages by Nitroglycerin. Nitric Oxide. 2010; 22.
  • Pei-Suen T; Vamsi A; Fung H. Dissociation between superoxide accumulation and nitroglycerin-induced tolerance.. J Pharmacol Exp Ther. 2009; 327.
  • Fung H; Tsou P; Bullita JB; Tran DC; Page NA; Soda D; Fung S. Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric. AAPS J. 2009; 10.
  • Tsou P; Addanki V; Haas JA; Page NA; Fung H. Role of glutaredoxin-mediated protein S-glutathionylation in cellular nitroglycerin tolerance. Journal of Pharmacology and Experimental Therapeutics. 2009; 329.
  • Turowski SG; Jank KE; Fung H. Inactivation of hepatic enzymes by inhalant nitrite--in vivo and in vitro studies.. AAPS J. 2007; 9.
  • Fung HL, Haas E, Raybon J, Xu J, Fung SM. Liquid chromatographic-mass spectrometric determination of endogenous gamma-hydroxybutyrate concentrations in rat brain regions and plasma.. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 807(2).
  • Wang EQ, Fung HL. Prazosin potentiates the acute hypotensive effects of nitroglycerin but does not attenuate nitrate tolerance in normal conscious rats.. J Cardiovasc Pharmacol. 2004; 43(3).
  • Wang EQ, Balthasar JP, Fung HL. Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocol.. Pharm Res. 2004; 21(1).
  • Khanna A, Rossman J, Caty MG, Fung HL. Beneficial effects of intraluminal nitroglycerin in intestinal ischemia-reperfusion injury in rats.. J Surg Res. 2003; 114(1).
  • Wang EQ, Fung HL. Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats.. AAPS PharmSci. 2002; 4(4).
  • Wang EQ, Lee WI, Fung HL. Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice.. Br J Pharmacol. 2002; 135(2).
  • Brazeau DA, Wang E, Fung HL, Lee, W.-I. cDNA Microarray Analysis of Vascular Gene Expression After Nitric Oxide Donor Infusions in Rats: Implications for Nitrate Tolerance Mechanisms.. AAPS PharmSci 2002. 2002; 4(2).
  • Wang EM; Soda DM; Fung H. Brit J. Pharmacol. 2001; 134.
  • Wang EQ, Soda DM, Fung HL. Nitroglycerin-induced relaxation of anorectal smooth muscle: evidence for apparent lack of tolerance development in the anaesthetized rat.. Br J Pharmacol. 2001; 134(2).
  • Khanna A, Rossman JE, Fung HL, Caty MG. Intestinal and hemodynamic impairment following mesenteric ischemia/reperfusion.. J Surg Res. 2001; 99(1).
  • Khanna A, Rossman JE, Fung HL, Caty MG. Attenuated nitric oxide synthase activity and protein expression accompany intestinal ischemia/reperfusion injury in rats.. Biochem Biophys Res Commun. 2000; 269(1).
  • Bauer JA, Fung HL, Zheng W, Kwon YW, Gopalakrishnan M, Triggle DJ. Continuous versus intermittent nitroglycerin administration in experimental heart failure: vascular relaxation and radioligand binding to adrenoceptors and ion channels.. J Cardiovasc Pharmacol. 1993; 22(4).
  • Gopalakrishnan M, Triggle DJ, Rutledge A, Kwon YW, Bauer JA, Fung HL. Regulation of K+ and Ca2+ channels in experimental cardiac failure.. Am J Physiol. 1991; 261(6 Pt).
  • McNiff EF, Yacobi A, Young-Chang FM, Golden LH, Goldfarb A, Fung HL. Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects.. J Pharm Sci. 1981; 70(9).
See all (15 more)

Books and Book Chapters:

  • Page NA; Fung H. Pharmacology of Nitrovasodilators. 2011.

Abstracts:

  • Brazeau GA; Haas C; Fung H; Fiebelkorn KD. Cultivating Future Clinical and Pharmaceutical Academic Research Leaders in PharmD Students. AJPE. 2002; 66.
  • Brazeau GA; Haas C; Fung H; Fiebelkorn KD. Preparing Students in Professional Practice Lab for the Professional Experience Program. AJPE. 1998; 62.

Professional Memberships:

  • Bureau of Pharmaceutical Science, International Pharmaceutical Federation; Expert member (2007)
  • American Association of Pharmaceutical Scientists; President (1997) (1987)

Presentations:

  • "A Pharmaceutical Research Journey with Nitroglycerin" , University of South Australia (2012)
  • "Pharmacological Tolerance from Oxidative Stress" , Department of Cardiology, University of South Australia (2012)
  • "Pharmacological Tolerance from Oxidative Stress" , University of Sydney (2012)
  • "Effective Presentation Skills--Academic Perspectives" AAPS National Biotechnology Conference, AAPS (2010)
  • "Aldehyde dehydrogenase 1 in the metabolism and bioactivation of organic nitrates" EB2010, FASEB (2010)
  • "Reactive metabolism runs amuck: a novel unifying mechanism of nitroglycerin action and tolerance" John G. Wagner Lecture, University of Michigan (2010)
  • "Mechanisms of L-arginine tolerance in endothelial cells" AAPS Annual Meeting, American Association of Pharmaceutical Scientists (2009)
  • "Role of Asymmetric dimethylarginine in L-arginine paradox: transport and metabolism considerations" AAPS Annual Meeting, American Association of Pharmaceutical Scientists (2009)
  • "Identification Of Cysteine Residues In ALDH2 Responsible" Experimental Biology 2009, FASEB (2009)
  • "Reactive Metabolism Runs Amuck: A Novel Unifying Mechanism of Nitroglycerin Action and Tolerance" University of Georgia, College of Pharmacy (2009)
  • "Reactive Metabolism Runs Amuck: A Novel Unifying Mechanism of Nitroglycerin Action and Tolerance" National Defense Medical Center, School of Pharmacy (2009)
  • "Selective activation of organic nitrates by, and inactivation of, ALDH isoforms" Experimental Biology 2009, FASEB (2009)
  • "Reactive Metabolism Runs Amuck: A Novel Unifying Mechanism of Nitroglycerin Action and Tolerance" Chugai Pharmaceuticals, Inc., Chugai Pharmaceuticals, Inc. (2009)
  • "Reactive Metabolism Runs Amuck: A Novel Unifying Mechanism of Nitroglycerin Action and Tolerance" 129th Annual Meeting of the Pharmaceutical Society of Japan, Pharmaceutical Society of Japan (2009)
  • "Nitroglycerin-induced matrix metalloproteinase-9 expression is linked to NF-?B activation in macrophages" AAPS Annual Meeting, AAPS (2008)
  • "Trans-Stimulated Efflux of Asymmetric Dimethylarginine Upon Arginine Challenge in Human Endothelial Cells" AAPS Annual Meeting, AAPS (2008)
See all (6 more)

Service Activities:

  • Scientific Program Chair, Pharmaceutical Sciences World Congress; Pharmaceutical Sciences World Congress Scientific Program Chair; Other (2007)
  • AAPS Student Chapter; Other
  • Graduate Affairs Committee; Member
  • Scientific Program Chair, Pharmaceutical Sciences World Congress, 2010; FIP/AAPS; Other

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

372 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 645-4843
hlfung@buffalo.edu